SOPHiA GENETICS Releases 2024 ESG Impact Summary

SOPHiA GENETICS ( (SOPH) ) has issued an announcement.

On May 16, 2025, SOPHiA GENETICS released its 2024 Environmental, Social, and Governance (ESG) Impact Summary, highlighting its commitment to sustainability and innovation in healthcare. The report outlines the company’s efforts in maximizing data efficiency, reducing environmental impact, and promoting employee engagement and diversity. With over 810 global clients, SOPHiA GENETICS continues to advance patient care through data-driven insights, while maintaining strong data protection and corporate governance standards.

The most recent analyst rating on (SOPH) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.

Spark’s Take on SOPH Stock

According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.

SOPH’s overall score reflects a balanced outlook. The company’s financial performance is hindered by ongoing profitability and cash flow challenges, despite revenue growth. Technical indicators suggest a neutral market sentiment, while valuation metrics are unattractive due to negative earnings. However, the earnings call reveals promising growth and strategic developments, particularly in the U.S. market, which partially offsets these challenges.

To see Spark’s full report on SOPH stock, click here.

More about SOPHiA GENETICS

SOPHiA GENETICS is a company operating in the healthcare industry, focusing on data-driven medicine. It offers genomic analysis solutions, utilizing its SOPHiA DDM™ platform to enhance oncology and rare disease discoveries. The company serves hospitals, laboratories, and biopharma customers across more than 73 countries, emphasizing sustainability and efficient data use.

Average Trading Volume: 49,493

Technical Sentiment Signal: Sell

Current Market Cap: $205.2M

Learn more about SOPH stock on TipRanks’ Stock Analysis page.